Publications by authors named "Wouter Hoefsloot"

Claim this Profile
E
Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system.
Jelmer Raaijmakers, Rob Aarnoutse, Lindsey Te Brake, Ralf Stemkens, Heiman Wertheim, Wouter Hoefsloot

J Antimicrob Chemother· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can the BACES score predict clinical outcomes in a Dutch cohort with nontuberculous mycobacterial pulmonary disease?
Arthur Lemson, Esmee van der Pol, Jakko van Ingen, Wouter Hoefsloot

ERJ Open Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Unique Combination of Heterozygous CFTR Gene Variants in a Person with Cystic Fibrosis and Mycobacterium abscessus Infection.
Arthur Lemson, Arthur Lemson, Cedric Bosteels, Jakko van Ingen, Monique Reijers, Wouter Hoefsloot

Respiration· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The spectrum of CFTR dysfunction in patients with nontuberculous mycobacterial pulmonary disease.
Arthur Lemson, Monique Reijers, Dineke Westra, Jakko van Ingen, Inez Bronsveld, Wouter Hoefsloot

Respir Investig· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medication adherence in patients with nontuberculous mycobacterial disease.
Arthur Lemson, Fleur Dijkhuizen, Ralf Stemkens, Arjan van Laarhoven, Reinout van Crevel, Wouter Hoefsloot

J Clin Tuberc Other Mycobact Dis· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of nontuberculous mycobacterial pulmonary disease requires a stepwise and multidisciplinary approach.
Arthur Lemson, Arjan van Laarhoven, Lisa Kurver, Ralf Stemkens, Rob Aarnoutse, Wouter Hoefsloot

Expert Rev Respir Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system.
Jelmer Raaijmakers, Mike M Ruth, Jodie A Schildkraut, Erik van den Hombergh, Rob E Aarnoutse, Wouter Hoefsloot

Int J Antimicrob Agents· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease.
Ralf Stemkens, Arthur Lemson, Simon E Koele, Elin M Svensson, Lindsey H M Te Brake, Wouter Hoefsloot

J Antimicrob Chemother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elderly patients with tuberculosis in a low-incidence country - Clinical characteristics, inflammation and outcome.
Cynthia van Arkel, Iris Storms, Lisa Kurver, Frank Smeenk, Pascal Wielders, Wouter Hoefsloot

J Infect· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial.
Sanne M H Zweijpfenning, Rob Aarnoutse, Martin J Boeree, Cecile Magis-Escurra, Ralf Stemkens, Wouter Hoefsloot

Chest· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rifampicin has no role in treatment of complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint.
Jakko van Ingen, Wouter Hoefsloot, Véronique Dartois, Thomas Dick

Eur Respir J· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clofazimine as a substitute for rifampicin improves efficacy of pulmonary disease treatment in the hollow-fiber model.
Sandra Salillas, Jelmer Raaijmakers, Rob E Aarnoutse, Elin M Svensson, Khalid Asouit, Wouter Hoefsloot

Antimicrob Agents Chemother· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-tuberculous mycobacteria disease pre-lung transplantation: A systematic review of the treatment regimens and duration pre- and post-transplant.
Johanna P van Gemert, Sofanne J Ravensbergen, Erik A M Verschuuren, Huib A M Kerstjens, Brigitte W M Willemse, Wouter Hoefsloot

Transplant Rev (Orlando)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful addition of topical antibiotic treatment after surgery in treatment-refractory nontuberculous mycobacterial skin and soft tissue infections.
Ralf Stemkens, Maarten Cobussen, Erik de Laat, Wouter Hoefsloot, Reinout van Crevel

Antimicrob Agents Chemother· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of rifampicin within the treatment of pulmonary disease.
Jodie A Schildkraut, Jelmer Raaijmakers, Rob Aarnoutse, Wouter Hoefsloot, Heiman F L Wertheim

Antimicrob Agents Chemother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monotherapy: Key cause of macrolide-resistant Mycobacterium avium complex disease.
Daniel Loewenstein, Lars van Balveren, Arthur Lemson, Nicolien Hanemaaijer, Wouter Hoefsloot

Respir Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MGIT Enriched Shotgun Metagenomics for Routine Identification of Nontuberculous Mycobacteria: a Route to Personalized Health Care.
Jodie A Schildkraut, Jordy P M Coolen, Heleen Severin, Ellen Koenraad, Nicole Aalders, Wouter Hoefsloot

J Clin Microbiol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amikacin Liposomal Inhalation Suspension in the Treatment of Lung Infection: A French Observational Experience.
Raphael Chiron, Wouter Hoefsloot, Jakko Van Ingen, Hélène Marchandin, Laurent Kremer

Open Forum Infect Dis· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case series.
Cynthia van Arkel, Martin Boeree, Cécile Magis-Escurra, Wouter Hoefsloot, Neeltje Carpaij

Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study.
Sanne Maria Henriette Zweijpfenning, Raphael Chiron, Sharon Essink, Jodie Schildkraut, Onno W Akkerman, Wouter Hoefsloot

Chest· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics.
Mike Marvin Ruth, Jelmer Raaijmakers, Erik van den Hombergh, Rob Aarnoutse, Elin M Svensson, Wouter Hoefsloot

Clin Microbiol Infect· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling.
Carlijn H C Litjens, Laurens F M Verscheijden, Celine Bolwerk, Rick Greupink, Jan B Koenderink, Wouter Hoefsloot

J Clin Pharmacol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease.
Rabi Danho, Jodie A Schildkraut, Sanne M H Zweijpfenning, Elin M Svensson, Lian J Pennings, Wouter Hoefsloot

Chest· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA Sequencing Elucidates Drug-Specific Mechanisms of Antibiotic Tolerance and Resistance in Mycobacterium abscessus.
Jodie A Schildkraut, Jordy P M Coolen, Sophie Burbaud, Jasper J N Sangen, Michael P Kwint, Wouter Hoefsloot

Antimicrob Agents Chemother· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of severe complex pulmonary disease with adjunctive amikacin and clofazimine standard regimen alone: a retrospective study.
Sanne M H Zweijpfenning, Stephan E P Kops, Martin J Boeree, Saskia Kuipers, Jakko van Ingen, Wouter Hoefsloot

ERJ Open Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis